Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation

Modern Pathology

Volumn 26, Issue 7, 2013, Pages 930-943

  Stricker, Thomas P ^a   Henriksen, Kammi J ^a   Tonsgard, James H ^a   Montag, Anthony G ^a   Krausz, Thomas N ^a   Pytel, Peter ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

kinase genes; malignant peripheral nerve sheath tumor; mitotic regulator; plexiform neurofibroma

Indexed keywords

PHOSPHOTRANSFERASE; BUB1B PROTEIN, HUMAN; CELL CYCLE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NEK2 PROTEIN, HUMAN; PDZ-BINDING KINASE; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MALIGNANT TRANSFORMATION; MITOSIS; NEUROFIBROMA; PLEXIFORM NEUROFIBROMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADOLESCENT; ADULT; CELL TRANSFORMATION; ENZYMOLOGY; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEURILEMOMA; PATHOLOGY; TISSUE MICROARRAY; YOUNG ADULT;

ADOLESCENT; ADULT; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEURILEMMOMA; NEUROFIBROMA, PLEXIFORM; PROTEIN-SERINE-THREONINE KINASES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84879915444     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.242     Document Type: Article

References (53)

1. Tonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol 2006;13:2-7. (Pubitemid 43963395)
2. Tucker T, Wolkenstein P, Revuz J, et al. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005;65:205-211. (Pubitemid 41022362)
3. Upadhyaya M. Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci 2011;16:937-951.
4. Mantripragada KK. Diaz de Stahl T, Patridge C, et al. Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array. Genes Chromosomes Cancer 2009;48:897-907.
5. Upadhyaya M, Spurlock G, Thomas L, et al. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum Mutat 2012;33: 763-776.
6. Bridge RS Jr., Bridge JA, Neff JR, et al. Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: A cytogenetic and molecular cytogenetic study. J Clin Pathol 2004;57:1172-1178. (Pubitemid 39486524)
7. Pytel P, Karrison T, Can G, et al. Neoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development. Int J Surg Pathol 2010;18:449-457.
8. Spurlock G, Knight SJ, Thomas N, et al. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: Correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol 2010;136:1869-1880.
9. Miller SJ, Jessen WJ, Mehta T, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009;1:236-248.
10. Subramanian S, Thayanithy V, West RB, et al. Genomewide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 2010; 220:58-70.
11. Yang J, Ylipaa A, Sun Y, et al. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin Cancer Res 2011;17:7563-7573.
12. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006;66:2584-2591.
13. Itani S, Kunisada T, Morimoto Y, et al. MicroRNA-21 correlates with tumorigenesis in malignant peripheral nerve sheath tumor (MPNST) via programmed cell death protein 4 (PDCD4). J Cancer Res Clin Oncol 2012;138:1501-1509.
14. Carroll SL. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol 2012;123:321-348.
15. King AA, Debaun MR, Riccardi VM, et al. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 2000;93:388-392. (Pubitemid 30622184)
16. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311-314. (Pubitemid 34526349)
17. Stucky CC, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): The Mayo Clinic experience. Ann Surg Oncol 2012;19:878-885.
18. Longhi A, Errani C, Magagnoli G, et al. High grade malignant peripheral nerve sheath tumors: Outcome of 62 patients with localized disease and review of the literature. J Chemother 2010;22:413-418.
19. Lee PR, Cohen JE, Tendi EA, et al. Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells. Neuron Glia Biol 2004;1:135-147.
20. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nat Biotechnol 2008;26:317-325. (Pubitemid 351355126)
21. Reis PP, Waldron L, Goswami RS, et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 2011;11:46.
22. Rodriguez FJ, Folpe AL, Giannini C, et al. Pathology of peripheral nerve sheath tumors: Diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 2012;123:295-319.
23. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003;100:9440-9445. (Pubitemid 37033947)
24. Dennis G Jr., Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:P3.
25. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
26. Huang da W, Sherman BT, Zheng X, et al. Extracting biological meaning from large gene lists with DAVID. Curr Protoc Bioinformatics 2009;27(Suppl): 13.11.1-13.11.13.
27. Barbagallo F, Paronetto MP, Franco R, et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J Pathol 2009;217:431-441.
28. Wang S, Li W, Lv S, et al. Abnormal expression of Nek2 and beta-catenin in breast carcinoma: Clinicopathological correlations. Histopathology 2011;59: 631-642.
29. Holtkamp N, Malzer E, Zietsch J, et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol 2008;10:946-957.
30. Perrone F, Da Riva L, Orsenigo M, et al. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol 2009;11:725-736.
31. Keizman D, Issakov J, Meller I, et al. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol 2009;94:383-388.
32. Perry A, Kunz SN, Fuller CE, et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002;61:702-709. (Pubitemid 34851773)
33. Levy P, Vidaud D, Leroy K, et al. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Mol Cancer 2004;3:20.
34. Rauen KA, Banerjee A, Bishop WR, et al. Costello and cardio-facio- cutaneous syndromes: Noving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet 2011;157:136-146.
35. Kraniak JM, Sun D, Mattingly RR, et al. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Mol Cell Biochem 2010;344:267-276.
36. Logarinho E, Bousbaa H. Kinetochore-microtubule interactions 'in check' by Bub1, Bub3 and BubR1: The dual task of attaching and signalling. Cell Cycle 2008; 7:1763-1768. (Pubitemid 351988741)
37. Rizzardi C, Torelli L, Barresi E, et al. BUBR1 expression in oral squamous cell carcinoma and its relationship to tumor stage and survival. Head Neck 2011;33:727-733.
38. Ando K, Kakeji Y, Kitao H, et al. High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Sci 2010;101:639-645.
39. Lee YK, Choi E, Kim MA, et al. BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. Br J Cancer 2009;101:504-510.
40. Du J, Du Q, Zhang Y, et al. Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A, cyclin A and cyclin E in invasive ductal breast carcinomas. Histol Histopathol 2011;26:761-768.
41. Scintu M, Vitale R, Prencipe M, et al. Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma. Cancer Lett 2007;254:298-307. (Pubitemid 47126694)
42. Yuan B, Xu Y, Woo JH, et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 2006;12: 405-410. (Pubitemid 43166128)
43. Grabsch H, Takeno S, Parsons WJ, et al. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer - association with tumour cell proliferation. J Pathol 2003;200:16-22. (Pubitemid 36592631)
44. Shichiri M, Yoshinaga K, Hisatomi H, et al. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 2002;62:13-17. (Pubitemid 34073977)
45. Pinto M, Vieira J, Ribeiro FR, et al. Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cell Oncol 2008;30:389-395.
46. Yamamoto Y, Matsuyama H, Chochi Y, et al. Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogenet 2007;174:42-47. (Pubitemid 46365984)
47. Fry AM. The Nek2 protein kinase: A novel regulator of centrosome structure. Oncogene 2002;21:6184-6194.
48. Fletcher L, Cerniglia GJ, Nigg EA, et al. Inhibition of centrosome separation after DNA damage: A role for Nek2. Radiat Res 2004;162:128-135. (Pubitemid 39100011)
49. Hayward DG, Newbatt Y, Pickard L, et al. Identification by high-throughput screening of viridin analogs as biochemical and cell-based inhibitors of the cell cycle-regulated nek2 kinase. J Biomol Screen 2010;15:918-927.
50. He F, Yan Q, Fan L, et al. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma. Hum Pathol 2010;41: 415-424.
51. Zhu F, Zykova TA, Kang BS, et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology 2007;133:219-231. (Pubitemid 47031135)
52. Park JH, Lin ML, Nishidate T, et al. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006;66:9186-9195. (Pubitemid 44521139)
53. Torres KE, Liu J, Young E, et al. Expression of 'drugable' tyrosine kinase receptors in malignant peripheral nerve sheath tumour: Potential molecular therapeutic targets for a chemoresistant cancer. Histopathology 2011;59:156-159.